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Objective: Several lines of evidence show that selenium (Se) has potential protective effects in osteoar-
thritis (OA), however the exact mechanism is still unclear. As interleukin-1b (IL-1b) is one of the key
proinﬂammatory cytokines contributing to the progression in OA, we investigated the effect of Se in
neutralizing the inﬂammatory effects of IL-1b on nitric oxide (NO) and prostaglandin E2 (PGE2)
production, and the signaling pathways involved.
Methods: Isolated primary human chondrocytes were pretreated with selenomethionine (SeMet) (0.5 mM
SeMet) for 24 h then co-treated without or with IL-1b (10 pg/ml or 50 pg/ml) for another 24 h followed
by RNA isolation. Gene expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2)
was determined by quantitative Real Time-Polymerase Chain Reaction. Culture media concentrations of
NO and PGE2 were determined by nitrite (NO2) assay and immunoassay respectively. For analysis of cell
signaling pathways, chondrocytes were pretreated with SeMet then stimulated with IL-1b for 0e45 min.
The activity of IL-1b signaling pathways was determined by Western blot screening of phosphorylation
states of signal transduction proteins.
Results: SeMet inhibited chondrocyte gene expression of IL-1b induced iNOS (31e54%, P¼ 0.031) and
COX2 (50e65%, P¼ 0.031) with corresponding reductions in both NO (19e47%, P¼ 0.031) and PGE2 (24
e32%, P¼ 0.031) production. Pretreatment with SeMet attenuated IL-1b induced activation of p38 MAPK
(39%, P¼ 0.039) but not the extracellular signal-regulated kinase pathways (ERK) 1/2, c-Jun N-terminal
kinases (JNK) or nuclear factor kB (NFkB).
Conclusions: This study elucidates one potential protective mechanism of Se, namely through the alter-
ation of cell signaling and downstream transcription of pro-inﬂammatory effects of IL-1b.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Selenium (Se) is an essential trace element involved in several
key metabolic activities: protection against oxidative damage;
regulation of immune and thyroid function; and fertility1,2.
Recently, a growing interest in the potentially protective role of Se
in Osteoarthritis (OA) has been generated based on
epidemiology3e5, genetic6 and transgenic animal studies7. Profound
Se deﬁciency is associatedwith the severe osteoarthropathy known
as KashineBeck Disease that affects individuals in China (as many
as 7 million) and neighboring regions3. Evidence for a role for Se in
OA comes from a large population based study in the US in whichto: Virginia Byers Kraus,
Center, Box 3416, Durham,
s Research Society International. Pa low but non-deﬁciency level of Se has been shown to be associ-
ated with OA presence and severity4,5. Moreover, a recent genetic
study showed that a variant of Deiodinase 2 (DIO2), which encodes
a selenoprotein involved in thyroid hormone activation, is associ-
ated with risk for developing OA6. While the exact mechanism is
still unclear, DIO2 is hypothesized to play a role in bone remodeling
in OA progression6. In mice, conditional knockout of the seleno-
cysteine tRNA gene, which is required for incorporation of Se into
selenoproteins, results in skeletal abnormalities and severe chon-
dronecrosis of articular cartilage resembling KashineBeck Disease,
as well as chondronecrosis of auricular and tracheal cartilages7.
In vitro studies have also suggested a protective effect of Se. For
instance, Se alters inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX2) gene expressions in response to lipo-
polysaccharide (LPS) stimulation in cultured macrophages8,9. Lack
of Se in vitro has been associated with elevated Prostaglandin E2
(PGE2) production in calcium ionophore stimulated endothelialublished by Elsevier Ltd. All rights reserved.
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exposure of chondrocytes in vitro to selenomethionine (SeMet)
could block IL-1 mediated inhibition of cartilage matrix macro-
molecule (collagen II and aggrecan) synthesis12. However, in the
same study, SeMet did not have signiﬁcant effects on iNOS or COX2
gene expression in the presence of high doses of interleukin-1b (IL-
1b) in bovine chondrocytes.
Taken together, these studies suggest an important role of Se in
maintaining normal cartilage metabolism and potentially pre-
venting OA. A better understanding of the mechanisms underlying
these Se-mediated protective effects could lead to the development
of novel therapeutic approaches for the prevention and manage-
ment of OA progression. We hypothesized that SeMet could block
proinﬂammatory gene expression induced by physiological doses
of IL-1b. In this studywe chose to investigate potential mechanisms
of Se mediated protective effects using physiological rather than
supra-physiological doses of IL-1b as used in the majority of prior
experiments12e16. Under these conditions we investigated the
magnitude of Se effects and the potential signaling pathways
involved in primary human chondrocytes.
Materials and methods
Chondrocyte isolation and culture
The samples used for this project were collected under approval
of the Duke IRB. The IRB deemed these samples surgical waste
tissues meeting the deﬁnition of research not involving human
subjects as described in (45CFR46.102(f)) and was not subject to
HIPAA (45CFR164.514(b)) as no information relating to patient
identity was obtained with the sample. Articular cartilage samples
were obtained as surgicalwaste tissues from19patients undergoing
total knee replacement surgery [mean age, 61.8 7.7 years]. The
isolated chondrocytes were used for experiments within the ﬁrst
three passages. Cartilage was harvested from non-lesional areas,
further minced, and subjected to pronase and collagenase digestion
to isolate primary chondrocytes, similar to previously published
methods17. The SW-1353 chondrosarcoma cell line was obtained
from the American Type Culture Collection (ATCC Manassas, VA).
IL-1b (R & D systems, Minneapolis, MN), concentrations of
10 pg/ml and 50 pg/ml were chosen on the basis of evidence for
physiological relevance (equivalent to concentrations in human OA
synovial ﬂuid)18,19. SeMet (Sigma, St Louis, MO), an organic form of
Se, was chosen as it is the primary dietary source of Se for human20.
A concentration of 0.5 mM SeMet was chosen for chondrocyte
cultures based on evidence of physiological relevance (equivalent
to concentrations in normal and OA human synovial ﬂuid21).
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay
Cell viability was assessed with the MTT assay based on the
ability of mitochondria of viable cells to convert solubleMTT into an
insoluble purple formazan reaction product. MTT (Sigma) solution
(5 mg/ml in Dulbecco’s modiﬁed Eagle’s medium (DMEM) without
phenol red) was added to cells in tissue culture for 2 h. The MTT
solution was aspirated, dimethyl sulfoxide (DMSO) was added
(200 ml/each well of 12 well plate) to solubilize formazan and
detection occurred by addition of 100 ml of the reaction mixture to
a 96 well plate format and reading at optical density (O.D.) 540 nm.
MTT assay results for the SW-1353 cell line were derived from two
independent experiments, performed in duplicate. MTT assay
results for primary chondrocytes were derived from two indepen-
dent experiments, performed in triplicate using two separate
primary chondrocyte cell lines.RNA isolation and real time reverse transcription-polymerase chain
reaction (RT-PCR)
Cell lysates, prepared by RNeasy Lysis Buffer (Qiagen Valencia,
CA) from each experimental condition, were ﬁrst homogenized
by passing them through a QIAshredder spin column (Qiagen,
Valencia, CA). The total DNA and RNA fractions were further
isolated using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. The iso-
lated total RNA was reverse transcribed into cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA) for Real Time RT-PCR analysis. The ABI Prism 7000
sequence detection system and relative quantiﬁcation software
(Applied Biosystems, Foster City, CA) were used for real-time
analyses. The ampliﬁcation for real-time RT-PCR used the following
Applied Biosystems primer and probe sets: 18S rRNA endogenous
control, Hs01075527_m1(iNOS), and Hs01573474_g1(COX2). The
real-time reactions were each performed in triplicate in a ﬁnal
volume of 25 ml.
mRNA quantiﬁcation and statistical analysis
Raw mRNA expression values were computed by 2ΔCt
formula22 with values normalized to 18S rRNA, where ΔCt repre-
sents the difference in Ct (threshold cycle) number of the 18S rRNA
gene and the iNOS or COX2 genes. Results were derived from
a total of six independent experiments for each dose of IL-1b for
COX2 and iNOS respectively, performed in triplicate, using a total
of 13 separate primary chondrocyte cell lines. The relative fold
changes in mRNA expression levels of iNOS and COX2 were
calculated by the 2ΔΔCt formula22, between three different treat-
ments (SeMet, IL-1b, SeMet and IL-1b treatment) and control
without treatment (no SeMet, no IL-1b). For the purposes of
graphical presentation, the relative mRNA level in cells without
treatment was set at 100%.
Raw mRNA expression data were evaluated by two-tailed
Wilcoxon matched pairs test comparing subgroups (n¼ 6 in each
group from 13 separate cell lines): (1) the control group and SeMet
pretreated group, (2) the IL-1b treatment group and IL-1b with
SeMet pretreatment group, and (3) the control group and IL-1b
treatment group. The nonparametric Wilcoxon matched pairs test
was chosen as it is appropriate for comparing two paired groups
allowing for the non-symmetrical distribution of the raw mRNA
expression data23.
Nitrite (NO2
) and PGE2 assays
NO2, one of the stable end products of NO concentrations were
determined by chemiluminescence using an Ionics/Sievers nitric
oxide (NO) analyzer (NOA 280, Sievers Instruments, Boulder, CO),
per the manufacturer’s instructions. Potassium iodide in acetic acid
was used as a reductant for NO2 analysis because of its speciﬁcity
for NO2. NO2 concentrations were determined by NO2 standards
prepared from sodium NO2 (Sigma, St Louis, MO) and normalized
to total DNA isolated from the corresponding chondrocytes. The
total DNA concentrationwas quantiﬁed byNanodrop 1000 (Thermo
Scientiﬁc, Wilmington, DE).
The PGE2 concentration of the collected culture medium was
determined using a competitive enzyme immunoassay based
Prostaglandin E2 Parameter Assay Kit (R&D Systems, Minneapolis,
MN). The data were normalized to total DNA isolated from the
corresponding chondrocytes. For samples with undetectable PGE2
levels (from the control groups without any treatment and the
SeMet pretreated alone groups), a value was assigned (13.5 pg/ml)
which is equal to half the lowest detection limit of the kit.
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 and PGE2 concentration quantiﬁcation and statistical analysis
Results of NO2 and PGE2 analyses were derived from a total of
six independent experiments for each dose of IL-1b for NO2 and
PGE2 respectively, using a total of 14 separate primary chondrocyte
cell lines. The fold changes in NO2 and PGE2 concentrations were
calculated for purposes of graphical presentation of NO2 and PGE2
concentration normalized to total DNA. The relative concentration
in cells without treatment (no SeMet, no IL-1b) was set at 100%.
NO2 and PGE2 concentration data were evaluated by two-tailed
Wilcoxon matched pairs test comparing subgroups (n¼ 6 in each
group from 14 separate cell lines): (1) the control group and SeMet
pretreated group, (2) the IL-1b treatment group and IL-1b with
SeMet pretreatment group, and (3) the control group and IL-1b
treatment group. All analyses were performed using GraphPad
version 5.0 (GraphPad Software, LA Jolla, CA). The nonparametric
Wilcoxon matched pairs test was chosen as it is appropriate for
comparing two paired groups allowing for the non-symmetrical
distribution of the NO2 and PGE2 data23.Western blot screening of signal transduction proteins
Chondrocytes from each experimental condition were collected
and homogenized in lysis buffer (10 mM HEPES, pH 7.5, 0.5% Triton
X-100, 5 mM EDTA, 5 mM EGTA and 1 M NaCl), supplemented with
protease inhibitor cocktail (Sigma, St. Louis, MO) and phosphatase
inhibitors (5 mM PMSF, 10 mM NaF, 25 mM B-glycerophosphate,
0.5 M DTT, 1 mM Na3V04). Whole cell lysates, were further sepa-
rated by SDS-PAGE, and transferred to nitrocellulose for immuno-
blotting. Membranes were blocked with 5% BSA in TBS/0.1% Tween
20 (TBS-T).
Polyclonal primary antibodies against Phospho-p38 MAPK
(Thr180/Tyr182), Total p38 MAPK, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204), Phospho-SAPK/JNK (Thr183/Tyr185), Phospho-
IKKa/b (Ser176/180) and Phospho-NFkB p65(Ser536) were
obtained from Cell Signaling Technology (Danvers, MA) and used at
1:1000 dilution. A monoclonal antibody against a-tubulin (Sigma)
was used as a normalization control at 1:10,000 dilution. Anti-
rabbit and anti-mouse IgG-HRP (Jackson ImmunoResearch, West
Grove, PA) secondary antibodies were used at a 1:5,000 dilution.
The resulting ﬁlms were scanned using CanoScan LiDE 70 (Canon,
Lake Success, NY) and the band intensities were quantiﬁed using
Adobe Photoshop CS and Image J (National Institutes of Health,
Bethesda, MD). The mean and standard error of the mean (SEM)
intensities of the phosphosignaling proteins were normalized to
the internal protein control (a-tubulin).Fig. 1. MTT cell toxicity assay for optimization of in vitro chondrocyte culture conditio
Effects of Se on cell viability were assessed with the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5
concentrations (0 mMe5 mM) of selenite or SeMet for 48 h. (B) Primary human chondrocytes
by 24 h co-treatment without or with 50 pg/ml IL-1b. Values shown are mean and SEM ofPhosphosignaling protein quantiﬁcation and statistical analysis
Raw intensity data of phosphosignaling proteins were normal-
ized to the internal protein control (a-tubulin). Results were
generated for three-time points 5, 30 and 45 min in the presence
and absence of SeMet, and were derived from three independent
experiments from three separate primary chondrocyte cell lines.
The total area under each curve (from 5 to 45 min) was determined.
The phosphosignaling protein intensities were evaluated by two-
tailedWilcoxonmatched pairs test comparing the response to IL-1b
induction at 5, 30 and 45 min between control (n¼ 9, without Se
pretreatment) and the Se pretreated (n¼ 9, 0.5 mM for the prior
24 h). The Wilcoxon matched pairs test was chosen as it is appro-
priate for comparing two paired groups allowing for the non-
symmetrical distribution of the phosphosignaling data.
Results
Inhibitory effect of SeMet on IL-1b induced iNOS gene expression
and NO2
 production
For cell toxicity assayswe initially compared two forms of Se, the
organic SeMet form, and the inorganic selenite. Based on the MTT
toxicity assay, SeMet showed no evidence of cellular toxicity at
concentrations up to 1 mM in SW-1353 cells [Fig. 1(A)] or isolated
primary chondrocytes. [Fig.1(B)] while selenite showed cell toxicity
beyond 1 mM.We subsequently selected SeMet at a concentration of
0.5 mM for all subsequent experiments. Twenty-four-hour treat-
ment with IL-1b at 10 pg/ml and 50 pg/ml signiﬁcantly induced
iNOS mRNA (w70-fold and w630-fold respectively) compared to
the control without IL-1b [Fig. 2(A and B)]. SeMet alone had no
effect on the basal iNOS mRNA level. Twenty-four-hour pretreat-
ment with SeMet signiﬁcantly repressed IL-1b induced iNOS steady
state mRNA level by w54% at 10 pg/ml IL-1b (P¼ 0.031), and by
w31% at 50 pg/ml IL-1b (P¼ 0.031). We further examined the effect
of SeMet on NO, the enzymatic product of iNOS. Because of the
short half-life of reactive NO, we measured NO2, which is a stable
downstream product of NO. SeMet pretreatment inhibited IL-1b
induced NO2 production, by 47% at 10 pg/ml IL-1b (P¼ 0.031), and
by 19% at 50 pg/ml IL-1b (P¼ 0.031) [Fig. 2(C and D)].
Inhibitory effect of SeMet on IL-1b induced COX2 gene expression
and PGE2 production
Next we investigated if pretreatment of SeMet could also affect
COX2 gene expression in the presence of IL-1b. Twenty-four-hourns.
-diphenyltetrazolium bromide) assay. (A) SW-1353 cells were cultured with different
were cultured for 24 h in the absence (control) or presence of 0.5 mM SeMet, followed
cell viability as a percentage of control (set at 100%).
Fig. 2. SeMet inhibited IL-1b induced iNOS gene expression and NO production in primary human chondrocytes.
Primary human chondrocytes were cultured for 24 h in the absence (control) or presence of 0.5 mM SeMet, followed by 24 h co-treatment without IL-1b (control) or with either
10 pg/ml (A and C) or 50 pg/ml (B and D) IL-1b. Gene expression for iNOS (A and B) was determined by RT-PCR normalized to 18S rRNA (average of triplicates for six independent
experiments). Corresponding culture media were analyzed for NO2 concentration (C and D). Data were normalized to total DNA of the corresponding chondrocytes. Values shown
are mean and SEM of iNOS or NO2 as a percentage of control (set at 100%). *P¼ 0.031.
A.W.M. Cheng et al. / Osteoarthritis and Cartilage 19 (2011) 118e125 121treatment with IL-1b at 10 pg/ml and 50 pg/ml signiﬁcantly
induced COX2 mRNA (w 53-fold and 120-fold respectively)
compared to the control without IL-1b [Fig. 3(A and B)]. SeMet had
no effect on the basal COX2 mRNA level. Twenty-four-hour
pretreatment with SeMet signiﬁcantly repressed IL-1b induced
COX2 steady state mRNA level by w65% at 10 pg/ml IL-1b
(P¼ 0.031) and byw50% at 50 pg/ml IL-1b (P¼ 0.031). We further
examined the effect of SeMet on PGE2 production, the downstream
enzymatic product of COX2. SeMet pretreatment inhibited IL-1b
induced PGE2 production, by 32% at 10 pg/ml IL-1b (P¼ 0.031), and
by 24% at 50 pg/ml IL-1b (P¼ 0.031) [Fig. 3(C and D)].Effect of SeMet on IL-1b induced signaling pathways
To determine whether the inhibitory effect of SeMet could be
associated with alterations of IL-1b induced signaling pathways, we
examined the phosphorylation status of signaling proteins in IL-1b
stimulated primary chondrocytes in the presence and absence of
SeMet. Stimulation of chondrocytes with IL-1b resulted in activa-
tion of MAPK kinases, p38 MAPK, ERK1/2 and JNK as well as NFkB
pathway signaling molecules, IKKa/b and NFkB p65, with phos-
phorylation peaking approximately 30 min after stimulation.
SeMet pretreatment alone did not affect the basal phosphorylation
level of any of the signaling molecules at time zero [Fig. 4(A), lane
ﬁve vs lane one]. In contrast, SeMet attenuated IL-1b induced
phosphorylation of p38 MAPK [Fig. 4(A), top row] but not the ERKs,
JNK, IKKa/b or NFkB p65 [Fig. 4(A)]. The total basal level of p38
MAPK was unaffected by either IL-1b or SeMet.
The mean phosphorylation level for each signaling molecule
was determined by Image J analyses (normalized to the a-tubulin
control) from three separate experiments [Fig. 3(B)]. SeMet
pretreatment only modestly (39%) but signiﬁcantly (P¼ 0.039)reduced the IL-1b induced activation of p38 MAPK based on the
total area under the curve (from 5 to 45 min), compared to the IL-1b
treated condition [Fig. 4(B)]. Pretreatment of SeMet did not affect
the IL-1b activation of the other molecules [Fig. 4(B)] nor total
p38 MAPK.Discussion
Elevated concentrations of the proinﬂammatory cytokine, IL-1,
are found in the synovial ﬂuid of OA joints24. IL-1 stimulates
several key proinﬂammatory mediators such as PGE2 and NO that
have been implicated in the pathogenesis of OA25,26. IL-1 stimu-
lates NO and PGE2 through regulation of iNOS and COX2
gene expression respectively27e29. Our data demonstrated that
pretreatment of chondrocytes with the antioxidant SeMet signiﬁ-
cantly inhibited both production of NO and PGE2 in response to IL-
1b. These results have potential clinical signiﬁcance based on
the known involvement of PGE2 and NO in joint metabolism
summarized below.
PGE2 has protean manifestations e some catabolic and some
anabolic. This is thought to be mediated by different EP receptors
such as EP2 and EP430-31. PGE2 upregulates matrix metal-
loproteinases (MMPs) that cause joint cartilage degradation32. PGE2
has been shown to positively modulate type II collagen gene
expression in cultured chondrocytes33. Furthermore, PGE2
promotes differentiation and proliferation of growth plate chon-
drocytes34,35. Sensitization of peripheral nociceptors by PGE2 is
believed to contribute to pain associated with inﬂammation36.
NO, another key mediator downstream of IL-1, has been
demonstrated to have an impact on cartilage homeostasis by
regulating the balance of anabolic and catabolic metabolism.
NO inhibits collagen and proteoglycan synthesis of cartilage in
Fig. 3. SeMet inhibited IL-1b induced COX2 gene expression and PGE2 production in primary human chondrocytes.
Primary human chondrocytes were cultured for 24 h in the absence (control) or presence of 0.5 mM SeMet, followed by 24 h co-treatment without IL-1b (control) or with either
10 pg/ml (A and C) or 50 pg/ml (B and D) IL-1b. Gene expression for COX2 (A and B) was determined by RT-PCR normalized to 18S rRNA (average of triplicates for six independent
experiments). Corresponding culture media were analyzed for PGE2 concentration (C and D). Data were normalized to total DNA of the corresponding chondrocytes. Values shown
are mean and SEM of COX2 or PGE2 as a percentage of control (set at 100%). *P¼ 0.031.
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In addition, NO has been shown to reduce IL-1 receptor antagonist
(IL-1ra) synthesis by chondrocytes39. Incubation of human articular
chondrocytes with the NO donor, sodium nitroprusside (SNP),
activates apoptotic gene expression40. NO can trigger apoptosis by
a mitochondria dependent mechanism that could be mediated
through regulation of expression of apoptotic related genes such as
caspase- 3 and 740,41. Furthermore, 3-nitrotyrosine, a stable product
formed by reaction of NO and reactive oxygen species, has corre-
latedwith IL-1b induced oxidative stress in aging and osteoarthritic
cartilage tissue42.
The Se mediated reduction in the NO and PGE2 production was
associated with corresponding reductions in iNOS and COX2 tran-
script levels. The direction and magnitude of the effect of SeMet on
the IL-1b induced NO production were similar to the effect on iNOS
mRNA expression. Therefore, the full effect of SeMet to modulate
NO production is likely mediated at a transcriptional level. The
inhibitory effect of SeMet on IL-1b induced NO production found in
our study was similar to the inhibitory effect shown previously by
others for the inorganic form of Se, namely selenite (5e10 mM), on
LPS-induced iNOS gene expression and NO production in murine
macrophages43,44.
In the case of PGE2 production, the magnitude of the inhibition
of PGE2 protein production wasw 50% less than the magnitude of
inhibition of COX2 gene expression. It is known that inhibition of
NO may lead to a corresponding compensatory release in PGE245.
Therefore, we believe the PGE2 results represent a combination of
downstream effects: SeMet inhibition of COX2 gene expression;
and SeMet inhibition of NO leading to increase in PGE2. These NO
and PGE2 data provide a plausible mechanism whereby Se may
play a protective role in OA.
Signaling pathways induced by IL-1b, that regulate NO and
PGE2 production, are sensitive to the redox state of cells, and canbe altered by natural antioxidants such as curcumin and capparis
spinosa15,46. Cytokines, including IL-1, have been shown to induce
NO and PGE2 production through MAPK and NFkB pathways in
human and rat chondrocytes16,47,48. We demonstrated that Se
partially inhibited the IL-1b induced phosphorylation of p38
MAPK, but not other MAPKs that are commonly involved in IL-1b
cell signaling. This is consistent with a past study that also showed
selective targeting of p38 MAPK by selenite, an inorganic form of
Se43. However, we cannot exclude the fact that Se may alter IL-1b
induced iNOS or COX2 gene expression through other signaling
pathways since our study was limited by having investigated only
a single form of Se, SeMet. Selenate (another inorganic form of Se)
has been shown to activate the PI3K/AKT pathway49, which
negatively regulates LPS induced COX250. In contrast to our
results, generated with human chondrocytes and physiologically
relevant concentrations of SeMet and IL-1b (10 and 50 pg/ml),
a previous study utilizing bovine chondrocytes and supra-physi-
ological doses of IL-1b (10 ng/ml), failed to observe an effect of
SeMet on IL-1b induced p38 kinase activity12. Thus, the results are
likely dependent on the dose and form of Se used. By the same
token, the dose and form of Se we chose may also explain why
SeMet did not have a signiﬁcant effect on phosphorylation of NFkB
p65 while high doses of selenite have been shown to inhibit NFkB
activity in cells other than chondrocytes, such as macro-
phages11,43,44. Finally, in contrast to other studies that measured
the DNA binding activities of NFkB, we examined the phosphor-
ylation level of NFkB p65 which might account for different results
between studies.
The mechanismwhereby Se modiﬁes the phosphorylation state
of p38 MAPK is unknown. Se may regulate the redox state and
redox state may alter the activity of upstream kinases or phos-
phatases that in turn control the phosphorylation status of p38
MAPK and hence the downstream signaling. Sulfhydryl groups of
Fig. 4. SeMet selectively blocked IL-1b induced p38 MAPK.
(A) Western blot analysis. Primary human chondrocytes were cultured for 24 h in the absence (control) or presence of 0.5 mM SeMet, and then co-treated with 50 pg/ml IL-1b
treatment for 0, 5, 30 and 45 min. Equal amounts of total cell lysate were separated by SDS-PAGE and analyzed by Western blot for the following proteins: Phospho-p38 MAPK
(Thr180/Tyr182), Total p38 MAPK, Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Phospho-SAPK/JNK (Thr183/Tyr185), Phospho-IKKa/b (Ser176/180) and Phospho-NFkB p65
(Ser536); a tubulin (bottom row) was used as a control for normalization. The results shown are representative of three independent experiments. (B) Quantiﬁcation of the effects of
SeMet on IL-1b induced phosphorylation of signaling proteins. Phosphoprotein signaling intensity was quantiﬁed by Image J analysis of Western blots for up to three-time points
from three independent experiments (as described in Fig. 3) with normalization to the internal control, a-tubulin. The normalized mean and SEM levels of phosphosignaling protein
intensity are shown for Phospho-p38 MAPK (Thr180/Tyr182), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Phospho-SAPK/JNK (Thr183/Tyr185), Phospho-IKKa/b (Ser176/180)
and Phospho-NFkB p65(Ser536). SeMet inhibited IL-1b activation of p38 MAPK signiﬁcantly but not the generation of the other phosphoproteins. *P¼ 0.039.
A.W.M. Cheng et al. / Osteoarthritis and Cartilage 19 (2011) 118e125 123protein tyrosine phosphatase can be reversibly oxidized and the
enzymatic activity regulated51. By analogy, regulation of redox state
by the antioxidant Se, might explain the Se related modulation of
IL-1b signaling. Further work remains to be done to elucidate the
mechanisms of Se mediated regulation of IL-1b signaling.
In conclusion, we showed that the antioxidant SeMet inhibited
IL-1b induced NO and PGE2 production throughmodulation of iNOS
and COX2 gene expression in primary chondrocytes. Our study also
showed that Se partially blocked IL-1 activation of the p38 MAPK
pathway. These results suggest that one mechanism whereby Se
may exert a protective effect is through regulation of the expression
of inﬂammation related genes, possibly mediated in part through
inhibition of IL-1b cell signaling.Author contributions
AWMC participated in the conception and design of the study,
isolating of primary chondrocytes, performing gene expression
studies, PGE2 assays, statistical analysis and drafted the manuscript.
TVS performed the NO2 assay and edited the manuscript. MB coor-
dinated andorganized surgicalwaste tissue collection and revised the
manuscript. VBK conceived of the study, supervised the project, and
participated in statistical analysis and manuscript preparation and
editing. All authors read and approved the ﬁnal manuscript.
Conﬂict of interest
The authors declare that they have no competing interests.
A.W.M. Cheng et al. / Osteoarthritis and Cartilage 19 (2011) 118e125124Acknowledgements
This study was funded by Center for Biomolecular and Tissue
Engineering International Fellowship (T32 GM00855-15 & 16) at
Duke (to AWMC), Osteoarthritis Research Society International
(OARSI) Scholarship (to AWMC), NIH/NIA Claude D. Pepper OAIC
5P30 AG028716 and NIH/NIAMS grant UO1 AR050898.
Supplementary material
Supplementary data associated with this article can be found in
the online version, at doi:10.1016/j.joca.2010.10.019.
References
1. Rayman MP. The importance of selenium to human health.
Lancet 2000;356(9225):233e41.
2. Ryan-Harshman M, Aldoori W. The relevance of selenium to
immunity, cancer, and infectious/inﬂammatory diseases. Can
J Diet Pract Res 2005;66(2):98e102.
3. Allander E. KashineBeck disease. An analysis of research and
public health activities based on a bibliography 1849e1992.
Scand J Rheumatol Suppl 1994;99:1e36.
4. Jordan J, Fang F, Arab L, Morris J, Renner J, Ngwenyama R, et al.
Low selenium levels are associated with increased odds of
radiographic knee and multijoint OA. Osteoarthritis Cartilage
2005;13(Suppl 1). S35.
5. Jordan J, Fang F, Schwartz T, Morris J, Renner J, Chen J, et al.
Low selenium levels are associated with increased odds of
radiographic hip osteoarthritis in African American and White
women. Osteoarthritis Cartilage 2007;15(Suppl 3):C33.
6. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ,
van der Wijk HJ, et al. Identiﬁcation of DIO2 as a new
susceptibility locus for symptomatic osteoarthritis. Hum Mol
Genet 2008;17(12):1867e75.
7. Downey CM, Horton CR, Carlson BA, Parsons TE, Hatﬁeld DL,
Hallgrimsson B, et al. Osteo-chondroprogenitor-speciﬁc dele-
tion of the selenocysteine tRNA gene, Trsp, leads to chon-
dronecrosis and abnormal skeletal development: a putative
model for KashineBeck disease. PLoS Genet 2009;5(8):
e1000616.
8. Vunta H, Belda BJ, Arner RJ, Channa Reddy C, Vanden
Heuvel JP, Sandeep Prabhu K. Selenium attenuates pro-
inﬂammatory gene expression in macrophages. Mol Nutr Food
Res 2008;52(11):1316e23.
9. Prabhu KS, Zamamiri-Davis F, Stewart JB, Thompson JT,
Sordillo LM, Reddy CC. Selenium deﬁciency increases the
expression of inducible nitric oxide synthase in RAW 264.7
macrophages: role of nuclear factor-kappaB in up-regulation.
Biochem J 2002;366(Pt 1):203e9.
10. Cao YZ, Reddy CC, Sordillo LM. Altered eicosanoid biosynthesis
in selenium-deﬁcient endothelial cells. Free Radic Biol Med
2000;28(3):381e9.
11. Zamamiri-Davis F, Lu Y, Thompson JT, Prabhu KS, Reddy PV,
Sordillo LM, et al. Nuclear factor-kappaB mediates over-
expression of cyclooxygenase-2 during activation of RAW
264.7 macrophages in selenium deﬁciency. Free Radic Biol
Med 2002;32(9):890e7.
12. Andriamanalijaona R, Kypriotou M, Bauge C, Renard E,
Legendre F, Raoudi M, et al. Comparative effects of 2 antioxi-
dants, selenomethionine and epigallocatechin-gallate, on cata-
bolic and anabolic gene expression of articular chondrocytes.
J Rheumatol 2005;32(10):1958e67.
13. Lazzerini PE, Capecchi PL, Nerucci F, Fioravanti A, Chellini F,
Piccini M, et al. Simvastatin reduces MMP-3 level in interleukin1beta stimulated human chondrocyte culture. Ann Rheum Dis
2004;63(7):867e9.
14. Zhou PH, Liu SQ, Peng H. The effect of hyaluronic acid on
IL-1beta-induced chondrocyte apoptosis in a rat model of
osteoarthritis. J Orthop Res 2008;26(12):1643e8.
15. Panico AM, Cardile V, Garuﬁ F, Puglia C, Bonina F,
Ronsisvalle G. Protective effect of Capparis spinosa on chon-
drocytes. Life Sci 2005;77(20):2479e88.
16. Thomas B, Thirion S, Humbert L, Tan L, Goldring MB, Bereziat G,
et al. Differentiation regulates interleukin-1beta-induced
cyclo-oxygenase-2 in human articular chondrocytes: role of
p38 mitogen-activated protein kinase. Biochem J 2002;362
(Pt 2):367e73.
17. Kuettner KE, Pauli BU, Gall G, Memoli VA, Schenk RK. Synthesis
of cartilage matrix by mammalian chondrocytes in vitro. I.
Isolation, culture characteristics, and morphology. J Cell Biol
1982;93(3):743e50.
18. Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ,
Dieppe PA. Synovial ﬂuid concentration of ﬁve different
cytokines in rheumatic diseases. Ann Rheum Dis 1990;49
(9):676e81.
19. Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelec G.
Determination of cytokines in synovial ﬂuids: correlation with
diagnosis and histomorphological characteristics of synovial
tissue. Ann Rheum Dis 1992;51(6):731e4.
20. Schrauzer GN. Selenomethionine: a review of its nutritional
signiﬁcance, metabolism and toxicity. J Nutr 2000;130
(7):1653e6.
21. Yazar M, Sarban S, Kocyigit A, Isikan UE. Synovial ﬂuid and
plasma selenium, copper, zinc, and iron concentrations in
patients with rheumatoid arthritis and osteoarthritis. Biol
Trace Elem Res 2005;106(2):123e32.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C
(T)) Method. Methods 2001;25(4):402e8.
23. Motulsky H: GraphPad Instat Version 3.0 The Instat guide to
choosing and interpreting statistical tests; 1990.
24. Goldring SR, Goldring MB. The role of cytokines in cartilage
matrix degeneration in osteoarthritis. Clin Orthop Relat Res
2004;427(Suppl):S27e36.
25. Jacques C, Gosset M, Berenbaum F, Gabay C. The role of IL-1
and IL-1Ra in joint inﬂammation and cartilage degradation.
Vitam Horm 2006;74:371e403.
26. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthritis
Cartilage 2008;16(Suppl 2):S15e20.
27. Vuolteenaho K, Moilanen T, Al-Saffar N, Knowles RG,
Moilanen E. Regulation of the nitric oxide production resulting
from the glucocorticoid-insensitive expression of iNOS in
human osteoarthritic cartilage. Osteoarthritis Cartilage 2001;9
(7):597e605.
28. Geng Y, Blanco FJ, Cornelisson M, Lotz M. Regulation of
cyclooxygenase-2 expression in normal human articular
chondrocytes. J Immunol 1995;155(2):796e801.
29. Charles IG, Palmer RM, Hickery MS, Bayliss MT, Chubb AP,
Hall VS, et al. Cloning, characterization, and expression of
a cDNA encoding an inducible nitric oxide synthase from the
human chondrocyte. Proc Natl Acad Sci U S A 1993;90
(23):11419e23.
30. Attur M, Al-Mussawir HE, Patel J, Kitay A, Dave M, Palmer G,
et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis
cartilage: evidence for signaling via the EP4 receptor.
J Immunol 2008;181(7):5082e8.
31. Li X, Ellman M, Muddasani P, Wang JH, Cs-Szabo G, van
Wijnen AJ, et al. Prostaglandin E2 and its cognate EP receptors
control human adult articular cartilage homeostasis and are
A.W.M. Cheng et al. / Osteoarthritis and Cartilage 19 (2011) 118e125 125linked to the pathophysiology of osteoarthritis. Arthritis
Rheum 2009;60(2):513e23.
32. Tung JT, Arnold CE, Alexander LH, Yuzbasiyan-Gurkan V,
Venta PJ, Richardson DW, et al. Evaluation of the inﬂuence of
prostaglandin E2 on recombinant equine interleukin-1beta-
stimulated matrix metalloproteinases 1, 3, and 13 and tissue
inhibitor of matrix metalloproteinase 1 expression in equine
chondrocyte cultures. Am J Vet Res 2002;63(7):987e93.
33. Goldring MB, Suen LF, Yamin R, Lai WF. Regulation of collagen
gene expression by prostaglandins and interleukin-1beta in
cultured chondrocytes and ﬁbroblasts. Am J Ther 1996;3
(1):9e16.
34. Schwartz Z, Gilley RM, Sylvia VL, Dean DD, Boyan BD. The
effect of prostaglandin E2 on costochondral chondrocyte
differentiation is mediated by cyclic adenosine 30,50-mono-
phosphate and protein kinase C. Endocrinology 1998;139
(4):1825e34.
35. Brochhausen C, Neuland P, Kirkpatrick CJ, Nusing RM, Klaus G.
Cyclooxygenases and prostaglandin E2 receptors in growth
plate chondrocytes in vitro and in situeprostaglandin E2
dependent proliferation of growth plate chondrocytes.
Arthritis Res Ther 2006;8(3):R78.
36. Dray A, Read SJ. Arthritis and pain. Future targets to control
osteoarthritis pain. Arthritis Res Ther 2007;9(3):212.
37. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric
oxide mediates suppression of cartilage proteoglycan
synthesis by interleukin-1. Biochem Biophys Res Commun
1994;200(1):142e8.
38. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H,
Takigawa M. Nitric oxide mediates interleukin-1-induced gene
expression of matrix metalloproteinases and basic ﬁbroblast
growth factor in cultured rabbit articular chondrocytes. J Bio-
chem 1998;123(3):431e9.
39. Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The
increased synthesis of inducible nitric oxide inhibits IL-1ra
synthesis by human articular chondrocytes: possible role in
osteoarthritic cartilage degradation. Osteoarthritis Cartilage
1996;4(1):77e84.
40. Maneiro E, Lopez-Armada MJ, de Andres MC, Carames B,
MartinMA, Bonilla A, et al. Effect of nitric oxide onmitochondrial
respiratory activity of human articular chondrocytes. Ann
Rheum Dis 2005;64(3):388e95.
41. Wu GJ, Chen TG, Chang HC, Chiu WT, Chang CC, Chen RM.
Nitric oxide from both exogenous and endogenous sourcesactivates mitochondria-dependent events and induces insults
to human chondrocytes. J Cell Biochem 2007;101(6):1520e31.
42. Loeser RF, Carlson CS, Del Carlo M, Cole A. Detection of
nitrotyrosine in aging and osteoarthritic cartilage: correlation
of oxidative damage with the presence of interleukin-1beta
and with chondrocyte resistance to insulin-like growth factor
1. Arthritis Rheum 2002;46(9):2349e57.
43. Kim SH, Johnson VJ, Shin TY, Sharma RP. Selenium attenuates
lipopolysaccharide-induced oxidative stress responses
through modulation of p38 MAPK and NF-kappaB signaling
pathways. Exp Biol Med (Maywood) 2004;229(2):203e13.
44. YunCH,Yang JS, KangSS, YangY, Cho JH, SonCG, et al. NF-kappaB
signaling pathway, not IFN-beta/STAT1, is responsible for the
seleniumsuppressionof LPS-inducednitric oxideproduction. Int
Immunopharmacol 2007;7(9):1192e8.
45. Fermor B, Weinberg JB, Pisetsky DS, Guilak F. The inﬂuence of
oxygen tension on the induction of nitric oxide and prosta-
glandin E2 by mechanical stress in articular cartilage. Osteo-
arthritis Cartilage 2005;13(10):935e41.
46. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A.
Suppression of NF-kappaB activation by curcumin leads to
inhibition of expression of cyclo-oxygenase-2 and matrix
metalloproteinase-9 in human articular chondrocytes: impli-
cations for the treatment of osteoarthritis. Biochem Pharmacol
2007;73(9):1434e45.
47. Masuko-Hongo K, Berenbaum F, Humbert L, Salvat C,
Goldring MB, Thirion S. Up-regulation of microsomal prosta-
glandin E synthase 1 in osteoarthritic human cartilage: critical
roles of the ERK-1/2 and p38 signaling pathways. Arthritis
Rheum 2004;50(9):2829e38.
48. Lianxu C, Hongti J, Changlong Y. NF-kappaBp65-speciﬁc siRNA
inhibits expression of genes of COX-2, NOS-2 and MMP-9 in
rat IL-1beta-induced and TNF-alpha-induced chondrocytes.
Osteoarthritis Cartilage 2006;14(4):367e76.
49. Heart E, Sung CK. Insulin-like and non-insulin-like selenium
actions in3T3-L1adipocytes. J CellBiochem2003;88(4):719e31.
50. Monick MM, Robeff PK, Butler NS, Flaherty DM, Carter AB,
Peterson MW, et al. Phosphatidylinositol 3-kinase activity
negatively regulates stability of cyclooxygenase 2 mRNA. J Biol
Chem 2002;277(36):32992e3000.
51. Monteiro HP, Ivaschenko Y, Fischer R, Stern A. Inhibition of
protein tyrosine phosphatase activity by diamide is reversed
by epidermal growth factor in ﬁbroblasts. FEBS Lett 1991;295
(1e3):146e8.
